On August 26, 2026, the U.S. Food and Drug Administration (FDA) approved daraxonrasib, marketed as RASONQUE, marking a significant advancement in the treatment of metastatic pancreatic adenocarcinoma. This approval endorses daraxonrasib as a first-in-class targeted therapy for this aggressive cancer type.

The indication for daraxonrasib includes adult patients with metastatic pancreatic adenocarcinoma who have previously undergone at least one systemic therapy or those who are deemed unsuitable for multiagent systemic therapy. This provides a new therapeutic option for patients with limited treatment alternatives.

The approval was formally announced by the FDA in their press release and product approval notice, underscoring the therapeutic importance of targeted agents in oncology. This development reflects ongoing efforts to expand treatment modalities for pancreatic cancer through innovative therapies.